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II. Instrumentation
Standard oligonucleotide synthesis was performed on solid supports using a Mermade MM6 synthesizer from Bioautomation. HPLC purification was carried out on an Agilent Infinity 1260. UV absorbance DNA quantification measurements were performed with a NanoDrop Lite spectrophotometer from Thermo Scientific. For structure assembly, Eppendorf Mastercycler 96-well thermocycler and Bio-Rad T100TM thermal cycler were used to anneal all DNA nanoparticles. Polyacrylamide gel electrophoresis (PAGE) was performed using 20x20 cm vertical
Hoefer 600 electrophoresis units. Agarose Gel Electrophoresis (AGE) were performed on Owl
Mini and Owl EasyCast horizontal gel systems. Gels were imaged by BioRad ChemiDoc MP system. Equilibrium dialysis was performed using single-use DispoEquilibrium Dialyzers (5000 Dalton molecular weight cut-off) from Harvard Apparatus. Fluorescence data were measured by BioTek Synergy H4 Hybrid Multi-Mode Microplate Reader. Multimode 8 scanning probe microscope and Nanoscope V controller (Bruker, Santa Barbara, CA) was used to acquire AFM images. DynaPro (model MS) molecular-sizing instrument was used to measure the particle size
distributions. Liquid Chromatography Electrospray Ionization Mass Spectrometry (LC-ESI-MS)
was carried out using a Bruker MaXis Impact™. TEM micrographs were acquired on FEI Tecnai 120 kV 12 microscope (FEI electron optics). Fluorescence cell imaging was performed with a Zeiss Axio Imager. Cytotoxicity studies were performed using the CellTiter96 kit from Promega according to the manufacturer's instructions. Apoptosis studies were analysed using a FACS Calibur flow cytometer. In vivo fluorescence measurements were performed using In Vivo Imaging System (IVIS).
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III. Solid-phase synthesis, purification
DNA synthesis was performed on a 1 µmole scale, starting from a universal 1000 Å LCAA-CPG solid-support. 1 Coupling efficiency was monitored after removal of the dimethoxytrityl (DMT) 5¢-OH protecting groups. DMT-dodecane-diol phosphoramidite (cat.# CLP-1114) was purchased from ChemGenes. Cyanine 3 Phosphoramidite (cat.# 10-5913-02) and Cy5.5 phosphoramidite (cat# 10-5961-95) were purchased from Glen Research. DMT-dodecane-diol and Cy3 phosphoramidite were dissolved in the acetonitrile under a nitrogen atmosphere in a glove box (<0.04 ppm oxygen and <0.5 ppm trace moisture). For DMT-dodecane-diol (0.1M, anhydrous acetonitrile) and Cy3 (0.1M, anhydrous acetonitrile) amidites, extended coupling times of 5 minutes were used respectively using 0. 25M 5-(ethylthio) as a 20-100 µL solution in Millipore water. Detection was carried out using a diode-array detector, monitoring absorbance at 260 nm. Retention times and for the products are summarized in Table   ST2 .
Alternatively, in the case of ssDNA, the crude product was isolated, dried, and resuspended in 1:1 H 2 O/8 M urea before loading to 20% polyacrylamide/urea gel. The gel was run at 250 V for 30 minutes followed by 500 V for 60 minutes with 1x TBE as the running buffer. The gel was then imaged and excised on TLC plate under a UV lamp. DNA was extracted from the excised gel slabs by crushing and soaking in 11-12 mL Milli-Q water at 60°C overnight. The solution was dried to approximately 1 mL before loading to Sephadex G-25 column. The purified DNA was quantified by its absorbance at 260 nm.
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IV. Sequences of DNA-polymer conjugates and characterization
The sequences of the DNA-polymer conjugates and DNA controls are presented in Supporting BKM120 was prepared as a 10 mM working solution in ethanol. Loading of the structures was achieved by adding 10 µL of BKM120 to an eppendorf, followed by solvent evaporation in open air to achieve a thin drug film. HE 12 -DNA conjugates in water were then added the drug film, mixed and followed by the addition of the assembly buffer (final solution: 100 µL at 10 mM in 1xTAMg buffer). The final solution was 100 µL with 100x excess BKM120 (1 mM). The mixture was vortexed heavily to allow re-suspension of the drug molecules, and was then annealed at 95°C to 10°C over 4 hours. Following the annealing step, removal of free BKM120 was achieved by preparative microcentrifugation (2 cycles of 14,000 rpm for 25 minutes, 4°C) to remove excess drug precipitate. Following microcentrifugation, the mixture was then purified by size-exclusion chromatography using Illustra MicroSpin G-25 Columns (GE Healthcare) using a modified protocol. (The columns were washed twice before resuspension in 1x TAMg. For the elution step, the spinning time was also optimized to ensure higher yield of recovered DNA nanoparticles).
a) BKM120 loading capacity of HE 12 -SNAs:
Reversed phase-HPLC was used to determine the amount of BKM120 loaded in the DNA nanoparticles, For HPLC, 60 µL of the purified supernatant was injected into a Hamilton PRP-1 5µm 100 Å 2.1 x 150mm column. The solvents used are 50 mM triethylammonium acetate (TEAA) buffer (pH 7.8) and HPLC grade acetonitrile. Typical retention times for the products are 27.4 minutes (DNA-polymer conjugate) and 28.733 minutes (BKM120) at 260 nm detection channel. The products were also detected using a drug-only channel at 320 nm (BKM120 maximum absorption peak). BKM120 loading capacity was determined by measuring the DNA peak areas at 260 nm and drug peak area 320 nm (see Figure SF3) . The values were compared with known concentration standards to obtain the number of drug molecules/DNA-conjugate strand. The loading capacity was also calculated based on the equation below:
Loading content (LC) % = mass of BKM120 in nanoparticles / total mass of loaded nanoparticles x 100%
The percent yield was calculated from the peak area of the recovered DNA product using known standards, and comparing it to initial starting concentration of 10 µM.
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Supporting Figure 5 . BKM120 loading capacity in HE 12 -SNAs calculated from RP-HPLC data.
b) UV-Vis spectroscopy
UV-vis measurements were used to ensure BKM120 encapsulation following the purification method. For each measurement, 100 µL of each of the purified solutions were dropped on a 96-well plate reader and measured through a BioTek Synergy H4 Hybrid Multi-Mode Microplate Reader. Data from UV-Vis spectroscopy was used to confirm the calculated drug concentration from RP-HPLC. Supporting Figure 6 . HPLC traces of collected dialysis fractions showing BKM120 release. The samples were detected at a BKM120-specific channel at 320 nm.
c) BKM120 release kinetics
S12
VI. Shelf-life of BKM120-loaded DNA nanoparticles:
The shelf-life of BKM120-loaded DNA nanoparticles was assessed by dynamic light scattering (DLS). The structures were stored at 4°C and room temperature, and the hydrodynamic radius was measured over a 4-week period.
Supporting Figure 7 . Shelf-life of BKM120-loaded DNA nanoparticles stored at 4°C. Dynamic light scattering (DLS) histograms showing the hydrodynamic radius of BKM120-loaded nanoparticles over time when stored at 4°C.
Supporting Figure 8 . Shelf-life of BKM120-loaded DNA nanoparticles stored at room temperature. Dynamic light scattering (DLS) histograms showing the hydrodynamic radius of BKM120-loaded particles over time when stored at room temperature.
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VII. Determination of critical micelle concentration (CMC)
To determine the CMC of HE 12 -DNA polymer conjugates, fluorescence spectra of 100 µM Nile Red in tris-acetate-magnesium (1 x TAMg) buffer were measured in the presence of increasing concentrations of HE 12 -DNA polymer conjugates. A stock solution of Nile Red 1 mM in acetone was used for all experiments. 1 µL of Nile Red stock in acetone was added and briefly incubated at room temperature to allow solvent evaporation. Series dilutions of DNA-polymer conjugates (in the range of 50 nM to 10 µM) were made up to a final volume of 100 µL. The mixture was subjected to a heat-cool cycle (95° C -4° C, over 4 hours). The samples were then transferred to a 96-well top-read microplate, and the plate was read using a Bioteck Synergy wellplate fluorimeter. Excitation was at 535 nm with a slit-width of 9 nm and emission was monitored between 560 nm and 750 nm. The CMC of HE 12 -DNA conjugates was investigated using fluorescence emission of a hydrophobic dye, Nile Red. This molecule is nearly non-emissive in bulk aqueous media, but its inclusive in a nonpolar microenvironment such as the core of HE 12 -SNAs results in an intense fluorescence signal. 3 A CMC of 0.5 µM ± 0.2 µM was calculated for HE 12 -DNA conjugates in 12.5 mM Mg 2+ . We anticipate the CMC to further decrease in the BKM120-loaded structures upon the encapsulation of the drug due to the additional stabilizing π-π interactions between drug molecules, and van der walls interactions with the carbon chains of the hydrophobic core.
Supporting Figure 9 . Fluorescence spectra of Nile Red encapsulation for determination of critical micelle concentration (CMC). a) Fluorescence spectra of Nile Red with varying concentration of DNA. b) Plot of log 10 [HE 12 -DNA] against maximal fluorescence intensity for HE 12 -DNA in the presence of 100 µM Nile Red. The CMC was calculated from the intersection of the two linear fits shown on the graph. The measurements were performed in triplicates. S15
VIII. Characterization of BKM120-loaded DNA nanoparticles Gel Mobility Shift Assays
Agarose gel electrophoresis was used to characterize the BKM120-loaded HE 12 -SNAs. In each case, 2.5% AGE was carried out at 4°C for 2.5 hours at a constant voltage of 80V. Typical sample loading is 15 picomoles with respect to the DNA, per lane (1.5 µL of 10 µM DNA).
Dynamic Light Scattering
Dynamic light scattering (DLS) experiments were carried out using a DynaPro™ 
Transmission Electron Microscopy
Samples (2 µL at 0.5 µM w.r.t. total DNA) were deposited on carbon film coated copper EM grids for one minute, followed by blotting off the excess liquid with the edge of a filter paper, and washing three times with 20 µL of water, before drying under vacuum. The samples were imaged using a Tecnai 12 microscope (FEI electron optics) equipped with a Lab6 filament at 120 kV. Images were acquired using a Gatan 792 Bioscan 1k x 1k Wide Angle Multiscan CCD Camera (Gatan Inc.). Contrast was adjusted automatically -note that in the presence of any highcontrast foreign matter, the structures resulted in being almost invisible. Images were analyzed using ImageJ, which required manually setting threshold levels and placing limits on the size and circularity of features to ensure correct particle picking. The area values obtained were converted into radii (for comparison with DLS), making the assumption that the features are circular, which can be readily validated by eye.
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Supporting Figure 12 . Additional TEM images of BKM120-loaded HE 12 -SNAs. Average diameter was calculated to be 21 ± 3 nm (N = 56).
IX. Buffer stability of HE 12 -SNAs
The stability of HE 12 -SNAs in buffer was evaluated by DLS measurements. Tris buffer containing different concentrations of magnesium or calcium was added to HE 12 -DNA conjugates and the mixture was annealed 95°C-4°C over 4 hours. In the case of DPBS buffer, different amounts of DPBS buffer were diluted from an initial 10X stock, mixed with HE 12 -DNA conjugates in water and annealed 95°C-4°C over 4 hours, prior to DLS analysis. 
Supporting
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Depletion of divalent cations causes the disassembly of structures into monomeric units. The assembly of HE 12 -SNAs in a Tris buffer containing no divalent cations, and in water is described below. 24 hours. The intensity of the lower mobility band was quantified over time (red line across the gel). The experiment was performed in triplicate.
Supporting Figure 17.
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Phosphorothioated DNA nanoparticles were synthesized according to a protocol reported by Fakhoury et. al. 5 The nuclease resistance experimental conditions for phosphorothioated particles are exactly the same as unmodified structures, described above.
Supporting Figure 19 . Denaturing PAGE gel of the FBS degradation products of phosphorothioated DNA nanoparticles. PS-DNA control: phosphorothioated DNA strand, PS-DNA nanoparticle: HE 12 -SNA with phosphorothioated DNA, DNA control: unmodified DNA strand.
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XI. Cellular uptake studies of DNA nanoparticles
Preparation of Cy3-labeled nanoparticles
Cy3-labeled HE 12 -SNAs were prepared by mixing Cy3-labeled HE 12 -DNA with unlabelled HE 12 -DNA strands at a 25:75 percent ration (DNA concentration 10 µM) followed by an annealing cycle 95°C-4°C over 4 hours. This percentage of labeled/unlabeled strands was observed to give the cleanest assemblies along with high fluorescence intensity for cellular uptake studies. 
Confocal Microscopy for Cellular Uptake of Cy3-labeled nanoparticles
HeLa (adenocarcinoma) cells were seeded at a density of 5 x 10 5 in 8-well slides. After 24 hours cells were incubated with Cy3-HE 12 -SNAs, HE 12 -SNAs, or Cy3-ssDNA (1 µM) at 37°C for 24 hours. Subsequently, cells were fixed with 2% paraformaldehyde/1X PBS. Cells were then washed with 1X PBS and mounted with Prolong Gold (Invitrogen, USA) and cured overnight at 4°C. Images were recorded using a Leica LS Microscope (Leica, Germany) and images were analyzed using the LASX software (Lecia, Germany).
Cellular uptake of Nile Red-loaded nanoparticles
Encapsulation of Nile Red
Nile Red was prepared as a 10 mM working solution in acetone. Loading of the structures was achieved by adding 20 µL of Nile Red to a glass vial, followed by solvent evaporation in open air to achieve a thin drug film. HE 12 -DNA conjugates in water were then added the drug film, mixed and followed by the addition of the assembly buffer (final solution: 100 µL at 10 mM in 1xTAMg buffer) with excess Nile Red (2 mM). The mixture was vortexed heavily to allow re-suspension of the drug molecules, and was annealed overnight (95°C-4°C over 4 hours). The mixture was purified by preparative centrifugation (15,000 x g, 4°C, 1 hour) between 2-4 times) and the concentration of encapsulated Nile Red was determined by fluorescence spectroscopy.
Fluorescence emission spectra of each sample were collected in triplicate by mixing a 25 µL aliquot of the purified sample with 75 µL of acetone and recording the emission spectra (Nile Red: S28 
Flow cytometry experiments
HeLa cells were seeded at a density of 5 x 10 5 in a 6 well plate. After 24 hours, the cells were incubated with HE 12 -SNAs + Nile Red or Nile Red alone (125 µL of sample added in a total media volume of 1 mL). The final concentration of Nile Red was 375 nM in both samples. After 12 hours of incubation, cells were detached, washed and resuspended in 1x PBS, followed by fixing with 2% paraformaldehyde. Samples were then processed using FACS FORTESSA. All measurements were performed in triplicates for error analysis. Nile Red images were acquired using Ar Ion laser 514 nm and Hoescht 3342 was used as a nuclear stain.
Supporting
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XII. In vitro cell studies
MTS Assay for BKM120 and DOX-BKM120 Cell Viability
Cell viability of HeLa cells after BKM120 treatments or in combination with Doxorubicin, was measured using the Cell-Titer Blue assay (Promega, USA). Briefly, cells were seeded in 96-well plates at a density of 1x10 5 . After 24 hours, BKM120 was added (final concentrations: 0.06, 0.12, 0.3, 1.52, 7.6 µM) for single treatments. When BKM120 was added in combination with Doxorubicin, BKM120 was varied between 0.12, 1.2, and 12 µM, while Doxorubicin was maintained at 0.1, 1, and 10 µM for each of those experiments. Subsequently after 24 hours, plates were analyzed at using a Bio Plater Reader using 560 nm Ex/590 nm emission. Data was plotted and analyzed using the GraphPad Prism Software.
Supporting Figure 24 . In vitro cytotoxicity of BKM120-loaded HE 12 -SNAs in HeLa cells.
Apoptosis studies in primary CLL patient cells
Primary B-CLL lymphocytes were maintained in RPMI complemented with 10% fetal bovine serum (FBS). BMS2 stromal cell line were maintained in Dulbecco's modified eagle medium (DMEM) supplemented with 10% FBS. BMS2 cells were plated at 70x10 4 cells/ml in 24-well plates before cocultured with primary B-CLL lymphocytes and incubated at 37ºC, 5% CO 2 .
For apoptosis assays, 3x10 6 B-CLL lymphocytes were plated in the presence or absence of stromal cell (BMS2) and incubated for 1 hour at 37ºC, 5% CO 2 . Cells were then treated with vehicle, nanoparticle, BKM120, and BKM120-loaded nanoparticles for 24 and 48 hours.
AnnexinV /propidium iodide analysis
Cells were harvested, washed with PBS then incubated with 1 µL Annexin V APC conjugated plus 0.5 µg/ml propidium iodide in 100 µL binding buffer for 15 min at room temperature. Cells were then analyzed with a FACSCalibur flow cytometer.
Cleaved caspase-3 analysis
Cells were harvested, washed with PBS then fixed for 10 min with 1% paraformaldehyde.
After washing, cells were permeabilized and non-specific sites blocked in PBS containing 3% FBS and 0.01% triton X100. Cells were then incubated for 1 hour with an anti-caspase-3 FITC conjugated antibody then analyzed with a FACSCalibur flow cytometer.
Immunostimulation TNF-α ELISA Assays
Immunostimulation assays were performed using RAW264.7 cells (ATCC), mouse monocytes. Briefly, cells were seeded in a 96-well plates at a density of 1x10 5 . Subsequently, after 24 hours, HE 12 -SNAs (2 µM), ssDNA (2µM), LPS 500 ng/mL (lipopolysaccharide), poly IC 10 ug/mL+Transfection, were added to the cells and incubated for 5, 24, and 48 hours. At each timepoint, supernatants were collected and frozen at -20°C. When all samples were collected, a TNF-α ELISA assay was performed according to the manufacturer's instructions (eBioscience) using the Instant ELISA TNF-α kit. Results were measured using a Bio plate reader at a wavelength of 630 nm and data was analyzed using the Graphpad Prism Software.
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Supporting Figure 25 . Flow cytometry data showing the amount of cleaved-caspase 3 in unstimulated primary CLL lymphocytes.
XIII. HSA binding studies:
HE 12 -SNAs were prepared as a 10 µM solution by thermal annealing 95°C-4°C over 4 hours.
For binding studies, 1 µL of HSA stock (526 µM) was added to 10 µL of DNA nanoparticles and incubated for 2 hour prior to analysis by agarose gel electrophoresis. For control experiments, 10 µL of HE 12 -DNA micellar structures were denatured by the addition of denaturing solution of urea (10 µL of each of 8 M urea) and depletion of magnesium cations prior to HSA addition in an EDTA containing TBE buffer, exposing their long aliphatic chains. Titrations of human serum albumin (HSA) prepared at 526 µM were added to the denatured HE 12 -SNA solution to yield final HSA dilutions of 1/1000, 1/100, 1/50, 1/10, 1/5, 1/2 and undiluted excess HSA (526µM stock).
The samples were analyzed under denaturing 20% PAGE.
As another control, DNA nanoparticles were incubated with 10% FBS for different time points, and subsequently denatured with 2x formamide (without the addition of proteinase K enzyme).
The structures were then run under 20% denaturing PAGE. To further investigate the interaction with HSA, we designed a Nile Red-loaded Cy3-DNA nanoparticle system ( Figure SF29 ). Due to the spectral overlap between Cy3 and Nile Red, simultaneous observation of released Nile Red molecules bound to HSA and the labeled DNA nanoparticles is possible under one fluorescence channel. In other experiments, we found that under gel electrophoretic conditions Nile Red molecules diffused out of the nanoparticle core, and a small portion of the dye molecules was found associated with HSA ( Figure SF29 ). These findings would hence allow us to track the mobility shift of the HSA protein by monitoring Nile Red fluorescence. Thus, the spectral overlap between Nile Red and Cy3 would then allow direct observation of HSA and Cy3 nanoparticles under a detection channel common for both Nile Red and Cy3. As illustrated in Figure SF23 , the lack of interaction between labeled DNA particles and HSA is demonstrated through the presence of two populations with different mobility shifts.
Supporting
Additionally, the amount of DNA was observed to remain mostly unchanged after HSA incubation Facility (approval # 2013-7350) . 12 CD-1 mice will be used to determine the biodistribution of Cy5.5-labeled HE 12 -SNAs by using the IVIS system. Mice were divided in 4 groups: control (4 mice), unlabeled HE 12 -SNAs (2 mice), Cy5.5 (2 mice), Cy5.5-ssDNA (2 mice) and Cy5.5-labeled HE 12 -SNAs. The biodistribution was evaluated after intraperitoneal or intravenous route of administration. HE 12 -DNA nanoparticles (100 µL at 17 µM total DNA) were injected in a single dose. The mice were then anesthetized with isoflurane, and then the fluorescence measured using the In Vivo Imaging System (IVIS), 15 mins, 30 mins, 1 hours, 2 hours, 4 hours, 6 hours and 24 hours after treatment. Survival time: 30 hours. Euthanasia: After 30 hours, the mice will be euthanized with isoflurane followed by cervical dislocation.
